Seroepidemiological Prevalence of Helicobacter pylori in the south of Tehran, Iran

Document Type : Original Article

Authors

1 Molecular Biology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran

2 Research Center for Prevention of Oral and Dental Diseases, Baqiyatallah University of Medical Sciences, Tehran, Iran

3 Research Center for Gastroenterology and Liver Diseases, Baqiyatallah University of Medical Sciences, Tehran, Iran

4 Amiran Oghyanoos Biotechnology Company, Tehran, Iran

Abstract

Background: Helicobacter pylori (HP) is one of the most widespread infections in the world especially in developing countries such as Iran. Evaluation of disease in Tehran, the capital of Iran, is serious due to overpopulation and also some lacks in sanitary facilities and economic conditions.
Objectives: The aim of this study is the evaluation of anti-HP antibodies in patients referred to a clinical lab in Tehran, Iran in 2019.
Methods: We evaluated anti-HP IgA and IgG antibodies by ELISA method. Positive and negative results were analyzed. During this study, the total number of 593 patients that were referred to the clinical laboratories due to symptoms of the disease was examined. Serum samples of these patients were collected and used for diagnosis via ELISA kit. Data were analyzed using SPSSv.17 through Kendall's tau-b test.
Results: From 593 patients, 451 have positive titer for both antibodies. In addition, 87% of patients have positive titer for IgG and 47.8% were positive for IgA titer. Findings also demonstrated that between the age groups, patients above 70 years old had the highest percentage of positive results for IgG titer (90%), and age-groups with 50-60 years old had the highest percentage of positive results for IgA titer (82%). Differences between genders were not statistically significant.
Conclusion: It seems that the number of patients suffering from this disease is rising in Tehran and even the lower age- groups are associated with this disease. For a reliable diagnosis, evaluation of both antibodies is recommended.

Keywords

Novelty in Clinical Medicine
Volume 1, Issue 1 - Serial Number 1
January 2022
Pages 55-58

Files

History

  • Receive Date: 16 November 2021
  • Revise Date: 18 November 2021
  • Accept Date: 25 December 2021

Share

How to cite

Statistics